Changes in Hong Kong stocks | Kingsley Biotech (01548) opened nearly 5% higher and reached a cooperation with Eli Lilly Tunelab, which is expected to continue to benefit the development of AI pharmaceuticals

The Zhitong Finance App learned that Kingsley Biotech (01548) opened nearly 5% higher, and the stock price surged by more than 14% yesterday. As of press release, as of press release, it rose 4.78% to HK$39, with a turnover of HK$27.204,800.

According to the news, in response to yesterday's stock price increase, Kingsley Biotech announced that the company signed an agreement to cooperate with Lilly TuneLab, an AI/machine learning drug discovery collaboration platform owned by Eli Lilly. According to the agreement, the Group will provide wet laboratory services to TuneLab participating companies at preferential rates to help generate experimental data and transform AI predictions into biological evidence data. The board believes that the agreement will further expand the Group's layout in the rapidly growing AI-driven drug discovery ecosystem, in line with its strategic direction of supporting biopharmaceutical innovation through integrated R&D solutions.

CITIC Construction Investment believes that Kingsley's AIDD-related revenue in the first half of this year is close to 40 million US dollars, and is expected to maintain rapid growth in the next few years. The Hong Kong stock placement was completed recently, and the capital raised is expected to be mainly used to build AIDD production capacity. As AI pharmaceuticals gradually move from computational science to deep integration with experimental science, the company is expected to continue to benefit.